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Abstract
Background: Human variant Creutzfeldt-Jakob Disease (vCJD) results from foodborne transmission of prions from
slaughtered cattle with classical Bovine Spongiform Encephalopathy (cBSE). Atypical forms of BSE, which remain mostly
asymptomatic in aging cattle, were recently identified at slaughterhouses throughout Europe and North America, raising a
question about human susceptibility to these new prion strains.
Methodology/Principal Findings: Brain homogenates from cattle with classical BSE and atypical (BASE) infections were
inoculated intracerebrally into cynomolgus monkeys (Macacca fascicularis), a non-human primate model previously
demonstrated to be susceptible to the original strain of cBSE. The resulting diseases were compared in terms of clinical
signs, histology and biochemistry of the abnormal prion protein (PrPres). The single monkey infected with BASE had a shorter
survival, and a different clinical evolution, histopathology, and prion protein (PrPres) pattern than was observed for either
classical BSE or vCJD-inoculated animals. Also, the biochemical signature of PrPres in the BASE-inoculated animal was found to
have a higher proteinase K sensitivity of the octa-repeat region. We found the same biochemical signature in three of four
human patients with sporadic CJD and an MM type 2 PrP genotype who lived in the same country as the infected bovine.
Conclusion/Significance: Our results point to a possibly higher degree of pathogenicity of BASE than classical BSE in
primates and also raise a question about a possible link to one uncommon subset of cases of apparently sporadic CJD. Thus,
despite the waning epidemic of classical BSE, the occurrence of atypical strains should temper the urge to relax measures
currently in place to protect public health from accidental contamination by BSE-contaminated products.
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Introduction
Classical Bovine Spongiform Encephalopathy (cBSE), the first
prion disease identified in cattle, was initially reported in 1986 in
the UK. Food-borne transmission of cBSE to humans was
observed ten years later as a variant form of Creutzfeldt-Jakob
Disease (vCJD) [1], leading to a major public health crisis.
This strain of cBSE is now rapidly disappearing as a result of
appropriate containment measures. However, atypical forms of
BSE have recently been identified in Europe and North America
as a consequence of cBSE testing performed in these countries [2–
4]. Because these cases are only found sporadically in older
animals ($8 years) coming to slaughter with few or no signs of
disease, it would be plausible to suppose that atypical forms of BSE
may have a lower virulence than cBSE and be innocuous to
humans. However, recent studies suggest that one of the two main
forms of atypical BSE, initially discovered in Italy and referred to
as the bovine amyloidotic spongiform encephalopathy (BASE),
might be at the origin of the cBSE epidemic: inoculation of the
BASE strain into transgenic and inbred mice showed an apparent
natural evolution towards the typical BSE strain [5,6]. Moreover,
a possible link has been suggested between BASE and one subtype
(MV2) of human sporadic CJD (sCJD) on the basis of biochemical
similarities [2,7]. In contrast to vCJD, sCJD is believed to occur de
novo without food-borne transmission. However, specific contam-
inating events by ingestion are difficult to rule out because human
prion diseases can have silent incubation periods exceeding
50 years, as demonstrated for kuru [8].
One strategy to evaluate the risk of BASE for humans consists in
assessing the susceptibility to disease transmission and the degree of
pathogenicity in a non-human primate model that has already been
shown to have characteristic clinical signs, histopathological lesions
and PrPres profiles following infections with either BSE or vCJD
[9,10]. We therefore inoculated cynomolgus macaque monkeys
(Macacca fascicularis) intracerebrally with BASE, cBSE and vCJD
prion strains. The BASE strain, prepared from brain extract of a 15-
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fatal disease than cBSE, and showed a biochemical signature similar
to that of the MM2 cortical subtype of human sCJD.
Methods
Cattle and human samples
The BASE inoculum (mix of brainstem and thalamus) from an
asymptomatic 15 year-old Italian Piemontese cow [2]: 250 mlo fa
10% brain homogenate in 5% glucose were inoculated intrace-
rebrally (i.c.) to a single macaque monkey. As controls, we used
two macaques inoculated i.c. with cBSE (brainstem from infected
UK cattle) and 4 macaques inoculated i.c. with human vCJD
[9,11]. Twenty-one subjects with a diagnosis of definite sCJD were
referred to the Medical Center in Verona, Italy during the period
2000–2004. Tissues were processed 4–18 hours post-mortem
according to established guidelines regarding safety and ethics.
Brains were cut longitudinally into two halves. Hemi-brains were
frozen and stored at 280uC until biochemical studies were
performed. The patient group encompassed all of the different
Table 1. Survival times of macaques inoculated
intracerebrally with brain homogenates from cattle with BASE
or BSE, and from humans with vCJD.
Strain Source Dose* Survival time (months)
BASE cattle 25 mg 26
BSE cattle 100 mg 40
BSE cattle 100 mg 40
vCJD human 40 mg 25
vCJD human 40 mg 30
vCJD human 40 mg 32
vCJD human 40 mg 37
*Amount of crude brain in 10% brain suspension inoculated intracerebrally. BSE
brain had a 10-fold greater concentration of PrPres than the BASE brain).
Animals inoculated with vCJD also received the equivalent of 8 mg of brain by
intra-tonsillar injection.
doi:10.1371/journal.pone.0003017.t001
Figure 1. Diagrammatic representation of histologic lesions. Topographic distribution of spongiosis (a and b) or gliosis (c and d) in BASE and
cBSE-infected primates. The lesions were scored from 0 to 4 (negative, light, mild, moderate, and severe).
doi:10.1371/journal.pone.0003017.g001
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(5 cases), MV1 (2), VV1 (1), MM2 (4), MV2 (6) and VV2 (3).
Non-human primate model
Cynomolgus macaques (Macacca fascicularis), captive-bred from
the Centre de Recherche en Primatologie (Mauritius), were
checked for the absence of common primate pathogens before
importation and handling in accordance to national guidelines.
Animals were maintained in biological security level 3 animal
facilities and clinical examinations were performed regularly. They
were humanely euthanized at the terminal stage of the disease, and
tissues were either fixed in Carnoy’s fluid for histological
examination or snap-frozen in liquid nitrogen and stored at
280uC for biochemical analyses.
Neuropathology and immunochemistry
Neuropathology and immunochemical detection of proteinase-
resistant prion protein (PrPres) and Glial fibrillary acidic protein
(GFAP)was performed on brain sections as previouslydescribed [12].
PrPres analysis
Tissues were homogenized to 20% (w/v) final concentration in a
5% sterile glucose solution. PrPres was purified according to a
protocol optimized for strain discrimination in ruminants [13,14]
(Discriminatory kit ref 3551177, BioRad, Marnes la Coquette,
France). Briefly, brain homogenates were first subjected to
proteolysis using either 0.4 mg (‘‘low’’ concentration) or 4 mg( ‘ ‘ h i g h ’ ’
concentration) of proteinase K/mg of brain (final concentration) in a
special buffer that partially protects the N-terminal part of PrPres in
order to increase strain discrimination, and then purified PrPres was
concentrated by centrifugation. Purified, non-human primate and
human samples were processed for Western blot analysis as
previously described: briefly, samples were separated by electropho-
resis on a 12% SDS polyacrylamide gel, blotted onto a nitrocellulose
membrane and detected by two mouse monoclonal antibodies: the
antibody from the BioRad Discriminatory kit, which targets the
epitope WGQPHGGX within the N-Terminal octarepeat region at
position 57–88, and 3F4, which targets the epitope MKHM in the
hydrophobic core at position 109–112. The protein bands were
visualized using a peroxidase-conjugated goat anti-mouse antibody
and chemiluminescence.
Results
Transmission characteristics of BASE and BSE
Clinical features. The BASE-inoculated macaque developed
clinical signs after a 21 months incubation period. Clinical signs
evolved slowly during the first four months, being limited to mild
tremor and myoclonus, without impairment in coordination or
locomotion,andwithoutanxietyoraggressiveness.Inthelastmonth,
the clinical picture rapidly worsened with evidence of major spatial
disorientation (the animal did not recognize its environment and
seemed lost in its cage), cognitive troubles (no recall of food location
and at intervals unaccountably stopped eating) and the appearance
of incoordination and disequilibrium; however, appetite and general
fitness were maintained. Euthanasia was performed at the terminal
Figure 2. Histopathology and PrPres immunostaining. Spongiosis, gliosis (GFAP staining) and PrPres deposition in frontal cortex and obex in
BASE- and cBSE-infected primates (original magnification 6200 for spongiosis and gliosis, 6400 for PrPres staining). Immunostaining of PrPres was
performed with 3F4 monoclonal anti-PrP antibody after proteinase K treatment as previously described [11]. No staining was observed in the brain of
control healthy primates (data not shown) in these conditions.
doi:10.1371/journal.pone.0003017.g002
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cBSE-inoculated animals had longer incubations periods
(37.5 months) and survivals (40 months) despite a presumably
larger infecting dose (100 mg containing a 10-fold higher PrPres
concentration). Moreover, the clinical presentation was very
different: animals exhibited aggressiveness and anxiety in
combination with incoordination, severe ataxic tremor, and loss of
appetite to the point of near starvation. The four animals inoculated
with human vCJD had a clinical evolution similar to that of animals
inoculated with BSE, though with less prolonged survivals (25 to
37 months).
Histopathology (Figures 1 and 2). In the BASE-inoculated
animal, the cortex showed widespread spongiosis and gliosis that
were especially prominent in the fourth and fifth layers. Spongiosis
was intense in the frontal cortex, with a loss of pyramidal cells in
the third and fifth layers. Lesions in the parietal cortex were even
more severe, with a complete disappearance of neurons in the
fourth layer. In the cBSE-inoculated animals, spongiosis and
gliosis were more discrete, and mainly affected the occipital cortex.
In the obex and cerebellum, the lesions (spongiosis and loss of
Purkinje and granular cells) were less pronounced in BASE than
cBSE-infected animals.
Immunohistochemistry (Figure 2). In the BASE-infected
animal, PrPres was distributed in a diffuse synaptic pattern (either
fine and sandy or roughly granular) with laminar enhancement in
the parietal cortex but no evidence of plaques, even when stained
with thioflavine T (data not shown), whereas cBSE-infected
animals had weak diffuse synaptic labeling but multiple
intensely-stained PrPres aggregates and characteristic plaques [9].
Strain discrimination by proteinase K sensitivity and
antibody reactivity
We made use of a technique developed to discriminate and
classify prion strains in small ruminants [14], based on the
differential sensitivity of the octapeptide and core regions of PrPres
proteins to proteinase K (PK) digestion. Controlled conditions of
proteolysis allowed a strain-dependent threshold of removal of the
octapeptides. This method, illustrated in Figure S1 (supplementary
data), was successfully applied for the diagnosis of the first case of
cBSE in a goat [15] and has now been validated by the European
Commission for regular use on field. We adapted this test to
primate prion strains, using only the higher PK concentration and
substituting the monoclonal antibody 3F4 as the anti-core
antibody to macaque and human PrP.
Figure 3. Electrophoretic analysis and differential sensitivity to proteolysis of PrPres in various prion diseases of primates and
humans. PrPres from brain homogenates (MM1 or VV2 sCJD, vCJD in humans, or primates experimentally infected with BASE, cBSE or vCJD inocula)
were purified under high concentrations of proteinase K, and detected with monoclonal antibodies recognizing either the core (3F4, panel A) or the
octapeptide region (panel B and C) of the protein. Frontal cortex and obex regions of BASE-infected primate were both analysed (lanes 3 and 4
respectively). Panel C is an overexposure of the autoradiography of Panel B to detect weak signals. The absence of octarepeat region reactivity in the
PrPres of the BASE in Panel C indicates a proportion at least ten fold lower than that of the vCJD or cBSE samples on the basis of a quantitative
analysis of chemiluminescence signal intensities.
doi:10.1371/journal.pone.0003017.g003
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highPKconcentrationareshowninFigure3.BothvCJD/cBSEand
BASE reacted strongly to anti-core antibody (Panel A). In contrast,
vCJD/cBSE also reacted weakly to anti-octapeptide antibody (Panel
B), whereas BASE reactivity was abolished (Panels B and C),
indicating a gradient of resistance to proteolysis of the N terminal
part of the PrPres among these strains. In cattle, the signal was
abolished for both cBSE and BASE strains (data not shown).
The method also revealed notable differences of octapeptide
sensitivity to PK in different types of human prion disease (figures 3
and 4). Comparisons of the relative signals with both anti-core and
anti-octapeptide antibodies for each sample indicated that the N
terminal part of PrPres from vCJD and the VV2 subtype of sCJD
werefarmoresensitive thaneithertheMM1 orVV1subtypes(Panel
B). The MV2 subtype showed a strong resistance to proteolysis that
was clearly different from the BASE-infected primate; however,
three of the four MM2 subtype cases exhibited the same signature as
BASE, and the fourth case had a significant proportion of PrPres
with anintactoctapeptide region,asshowninfigure5,indicatingthe
coexistence of two types of PrPres (the majority being type 2).
All four cases had clinical features consistent with the MM2
subtype as described by Gambetti et al [16]: comparatively long
illnesses dominated by cognitive impairment followed by aphasia,
and later in the course of illness the appearance of pyramidal and
extrapyramidal signs together with myoclonus, but no cerebellar
signs. Neuropathology was also typical of the MM2 subtype, with
major cortical spongiosis and little or no involvement of the
cerebellum (Table 2 summarizes the clinical, laboratory, and
neuropathological features of each case).
Discussion
We have shown that BASE, the first identified atypical strain of
BSE[2],originatingfromasymptomaticcattle,istransmissiblebyi.c.
inoculation to a species of non-human primate. Although this
observation concerned only one animal, its survival was substantially
shorter than for all the macaques inoculated with classical BSE as
well as the majority of those inoculated with human vCJD.
Moreover, in earlier experiments by others on a total of 6 macaques
inoculated i.c. with 50 mg of cBSE brain, none had an incubation
period of less than 30 months [17], and humanized transgenic mice
havebeenfoundtobehighlysusceptibletoinfectionwithBASE,and
completely resistant to infection with cBSE [18]. If BASE is more
pathogenic than classical BSE for primates, it could indicate a more
readily transmissible infection from cattle to humans than previously
suspected. A preliminary trial of oral transmission is currently
ongoing for alimentary risk assessment: 49 months after oral dosing
there is no indication of transmission; however, the incubation
period following similar oral challenge with cBSE in an already
completed experiment was 60 months.
The disease induced by BASE was different in all respects from
that induced by classical BSE. The clinical presentation was
characterized by mild tremors and myoclonus, progressing to a
marked cognitive disorder, including spatial disorientation but
without anxiety, aggressiveness or loss of appetite. In contrast,
cBSE presented signs of anxiety and aggressiveness together with
progressive difficulties in locomotion as well as cerebellar signs
(major ataxia), and severe decrease of appetite with concurrent
weight loss. The widespread spongiform lesions and loss of
pyramidal cells in the third and fifth layers of the frontal cortex
together with the severe parietal lesions could explain the
prominent cognitive signs and the spatial disorientation seen in
the BASE-infected monkey, contrasting with the severity of lesions
in the obex and cerebellum consistent with the incoordination seen
in animals inoculated with cBSE. Amyloid plaques, the hallmark
of BASE in cattle, are not produced in the Macaque monkey, and
conversely, cBSE does not produce plaques in cattle, but does so in
the Macaque [9], a clear indication that plaque deposition
depends as much on the host as the prion strain.
Figure 4. Electrophoretic analysis and differential sensitivity to proteolysis of PrPres in different subtypes of CJD. PrPres from human
brain homogenates (MM1, MV1, VV1, MM2, MV2 or VV2 subtypes of sCJD, and vCJD) were purified under high concentrations of proteinase K, and
detected with monoclonal antibodies that recognize either the core (3F4, Panel A) or the octapeptide region (Panel B) of the protein. The proportion
of PrPres with an intact octarepeat region after PK exposure in VV2 and human (or macaque) vCJD was estimated to be only one-tenth and one-
twentieth as high as in an MM1 sub-type of sCJD, respectively.
doi:10.1371/journal.pone.0003017.g004
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treatment and detection using two antibodies reacting with either
an epitope in the N terminal octapeptide repeat region or the core
of PrP, BASE and cBSE were clearly distinguishable in primate.
BASE was detectable only by the core antibody, whereas cBSE
was detectable by both antibodies. We estimated that the
proportion of octapeptide-resistant PrPres molecules in the BASE
brain homogenate was only a small fraction (#1/10) of that of the
cBSE brain homogenate. The difference in octapeptide sensitivity
to PK between cBSE and vCJD in macaques on the one hand, and
Type 1 sporadic CJD in humans on the other hand, is similar to
what was observed between cBSE and classical scrapie in sheep.
This method can now be used to test both ruminant and human
samples to identify similarities and differences in their molecular
protein signatures, and to implement the classification of ruminant
and possibly human strains.
Although classical epidemiological studies have not found any
link between scrapie in sheep and goats and human CJD, newer
molecular biological studies now indicate that about half of all
cases of scrapie are due to previously undetected atypical strains
[19] that are experimentally transmissible to sheep and mice [20].
Their risk for humans is unknown and is the subject of current
studies in experimental models, including primates. cBSE has been
shown to be responsible for human cases of vCJD, but the
comparative risk for humans of BASE and other atypical strains of
BSE is still unknown, and its clarification will require many years
of epidemiological surveillance and molecular biological testing of
both bovine and human populations.
The first cases of BASE in cattle had PrPres electrophoretic
profiles similar to the MV2 subtype of sporadic CJD patients [2]
that, together with the presence of amyloid plaques in both the cattle
and the patients, suggested a possible link between BASE and this
subtype of sCJD. However, our PrPres typing technique has shown
that, in the primate, PrPres of other MV2 sCJD patients exhibited a
resistance to proteolysis different from the BASE-infected primate,
whereas PrPres from vCJD-infected patients and primates behave
similarly. This observation, together with the absence of amyloid
plaques in the BASE-infected primate, weakens the likelihood of a
direct link between BASE and MV2 subtype sCJD patients.
In contrast, the specific signature of PrPres in the BASE-infected
primate was similar to that seen in three of four patients with the
MM2 cortical subtype of sporadic CJD [7]. It is interesting that an
Figure 5. Electrophoretic analysis and differential sensitivity to proteolysis of PrPres in different MM2 CJD patients. PrPres from
human brain homogenates (MM2 or MV2 subtypes of sCJD) and from primate experimentally infected with BASE were purified under high
concentrations of proteinase K, and detected with monoclonal antibodies that recognize either the core (3F4, Panel A) or the octapeptide region
(Panel B) of the protein.
doi:10.1371/journal.pone.0003017.g005
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BASE-infected macaque –the absence of cerebellar involvement –
is also a common element in patients with the MM2 subtype of
human sporadic CJD (Supplementary Figure S2). However, as
illustrated by the clinical details of our four tested MM2 cases,
there is considerable patient-to-patient variation, just as there can
be variation among individual animals experimentally inoculated
with a given strain of TSE. [21,22].
It is not known whether atypical strains of BSE have been
circulating for years, or represent new forms of disease, and
continuing research is clearly needed to answer both this and the
equally important question about a possible relationship to at least
certain forms of what are presently regarded as sporadic cases of
human disease (sCJD) [4,23]. Moreover, the BASE strain has been
described to evolve naturally towards BSE after successive
transmissions in inbred mice [6]. The stability and pathogenicity
of this strain in humans remains to be determined, and it is worth
recalling that the stability of the cBSE/vCJD strain, which retains
its specific molecular signature in different infected hosts, is the
exception rather than the rule. As has been previously observed
[24–26], one patient (Case No. 4, cf. figure 5 sample MM2#4)
exhibited both types of PrP, i.e. type 2 typical of the MM2 subtype
and type 1 observed in the MM1 subtype. On the one hand, this
demonstrates the interest of such a simple biochemical test to
refine PrP analysis, and on the other hand it raises a question
about the existence of different PrPres signatures in the same
patient, i.e., different prion strains linked to multiple infections or
to variants selected by the host.
In summary, we have transmitted one atypical form of BSE
(BASE) to a cynomolgus macaque monkey that had a shorter
incubation period than monkeys infected with classical BSE, with
distinctive clinical, neuropathological, and biochemical features;
and have shown that the molecular biological signature resembled
that seen in a comparatively uncommon subtype of sporadic CJD.
We cannot yet say whether BASE is more pathogenic for primates
(including humans) than cBSE, nor can we predict whether its
molecular biological features represent a clue to one cause of
apparently sporadic human CJD. However, the evidence present-
ed here and by others justifies concern about a potential human
health hazard from undetected atypical forms of BSE, and despite
the waning epizoonosis of classical BSE, it would be premature to
abandon the precautionary measures that have been so successful
in reversing the impact of cBSE. We would instead urge a gradual,
staged reduction that takes into account the evolving knowledge
about atypical ruminant diseases, and both a permanent ban on
the use of bovine central nervous system tissue for either animal or
human use, and its destruction so as to eliminate any risk of
environmental contamination.
Table 2. Summary of MM2 subtype sporadic CJD patients.
Case # 123 4
Sex Female Male Male Female
Age at onset 60 years 59 years 59 years 69 years
Duration of illness 24 months 9 months 6 months 16 months
Onset Progressive memory impairment
beginning with episodic memory
disturbance, then attention loss,
spatial and temporal orientation
Depression, insomnia,
headache. Episodic memory
impairment and poor language
Memory disturbance Depression, memory
impairment
Evolution Progressive cognitive decline,
motor and sensory aphasia,
progressive global impairment
of all cortical functions, with
assistance needed for self care.
Pyramidal signs mainly
characterized by hypereflexia
Worsening of memory
impairment, motor aphasia,
intellectual decline, progressive
loss of all cortical functions.
Myoclonus, urinary incontinence,
loss of self-care
Confusional state, global
impairment of higher cortical
functions
Progressive cognitive decline,
characterized by global
impairment of all cortical
functions. Myoclonus
Terminal stage Diffuse spastic rigidity; Pyramidal
signs; dystonic movements and
sporadic myoclonic jerks
Akinetic mutism No information available Akinetic mutism
MRI Cortical atrophy with hyper-
intensity of the head of
Caudate nucleus and Putamen,
in T2-weighted images
Normal (early stage of illness) Normal (early stage of illness) Hyperintensity in T2 weighted
images of fronto-temporal
cortical ribbon
SPECT 99mTc-ECD Not done Hypo-perfusion of frontal, parietal
and temporal cortices, bilaterally.
Normal perfusion of subcortical
ganglia and cerebellum
Hypo-perfusion of frontal,
parietal and to a lesser extent
temporal cortices
Not Done
MMSE 10/30 Not done Not done Not reported
CSF 14-3-3 protein Positive Positive Not done Negative
EEG Diffuse slowing. Diffuse slowing Diffuse slowing Periodic sharp waves
Neuropathology Cortical spongiosis, Cerebellum
relatively spared
Cortical spongiosis, Cerebellum
relatively spared
Cortical spongiosis, normal
cerebellum
Cortical spongiosis, cerebellum
relatively spared
Type PrPres Type 2 Type 2 Type 2 Type 1+2
Resistance of N-terminal
part to proteolysis
No (BASE infected primate-like) No (BASE infected primate-like) No (BASE infected primate-like) Yes
doi:10.1371/journal.pone.0003017.t002
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Figure S1 Resistance to proteolysis of different prion strains in
sheep. PrPres from brain homogenates of sheep infected with
classical scrapie, experimental cBSE, or atypical Nor-98 scrapie,
and of an uninfected control sheep. Samples were purified using
low (odd lanes) or high (even lanes) concentrations of proteinase K,
and visualized with monoclonal antibodies that recognize either
the core region (Panel A) or the octapeptide region (Panel B) of the
protein. With the lower concentration of PK used in the
purification step (in order to maximize test sensitivity) of one
widely utilized BSE screening test [13], all three strains gave a
positive result with both the anti-core and anti-octapeptide
antibodies (odd lanes). Using a higher concentration of PK (even
lanes) did not alter the positivity with either antibody for classical
scrapie, but the cBSE strain no longer reacted with the anti-
octapeptide antibody while Nor98 did not react with either
antibody. Thus, by using the higher concentration of PK and two
different antibodies, it is possible to discriminate between all three
strains.
Found at: doi:10.1371/journal.pone.0003017.s001 (2.51 MB TIF)
Figure S2 Lesion profiles in cBSE- and BASE-infected ma-
caque, and in MM2 sporadic CJD patients. The lesions were
scored from 0 to 4 (negative, light, mild, moderate, and severe) for
the different following gray matter regions: frontal (FC), temporal
(TC), parietal (PC) and occipital (OC) neocortices, hippocampus
(HI), parasubiculum and entorhinal cortex (EC), neostriatum (ST)
(nuclei caudatus and putamen), thalamus (TH), substantia nigra
(SN), midbrain periventricular gray (PG), locus ceruleus (LC),
medulla (ME) (periventricular gray and inferior olive) and
cerebellum (CE). Scoring for MME sCJD patient was issued from
Parchi et al. [7].
Found at: doi:10.1371/journal.pone.0003017.s002 (1.52 MB TIF)
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